Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial

Nat Med. 1996 Oct;2(10):1109-15. doi: 10.1038/nm1096-1109.


A T-cell receptor (TCR) peptide vaccine from the V beta 5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Autoimmune Diseases / immunology
  • Autoimmune Diseases / therapy*
  • Disease Progression
  • Double-Blind Method
  • Female
  • HLA-DR Antigens / analysis
  • HLA-DRB1 Chains
  • Humans
  • Immunotherapy, Active*
  • Interleukin-10 / physiology
  • Male
  • Middle Aged
  • Multiple Sclerosis / immunology
  • Multiple Sclerosis / therapy*
  • Myelin Basic Protein / immunology
  • Peptide Fragments / immunology*
  • Pilot Projects
  • Receptors, Antigen, T-Cell, alpha-beta / immunology*
  • T-Lymphocyte Subsets / immunology
  • Th2 Cells / immunology
  • Vaccines / administration & dosage
  • Vaccines / immunology*


  • HLA-DR Antigens
  • HLA-DRB1 Chains
  • Myelin Basic Protein
  • Peptide Fragments
  • Receptors, Antigen, T-Cell, alpha-beta
  • Vaccines
  • Interleukin-10